The GLP-1 battle heats up with new preliminary data from Eli Lilly showing that patients using its weight loss drug Zepbound lost more weight on average in 72 weeks than those on Novo Nordisk’s Wegovy.
The post Video: Battle of the Bulge – Wegovy vs. Zepbound appeared first on MedCity News.
Leave a comment